June 4, 2025 — RadNet, Inc., a provider of high-quality, cost-effective diagnostic imaging services and digital health solutions through its wholly-owned subsidiary DeepHealth, recently announced it has completed the acquisition of See-Mode Technologies, a global innovator in AI for ultrasound imaging. See-Mode’s initial applications to detect and characterize thyroid nodules and breast lesions in ultrasound imaging improve diagnostic accuracy and enhance clinical workflows by generating standardized reports.1 These applications and others to be developed in the future using See-Mode’s technology and expertise will strengthen DeepHealth’s leadership in population health solutions.
Dr. Howard Berger, president and chief executive officer of RadNet, commented, “Thyroid cancer is one of the fastest growing cancer diagnoses worldwide2 and, alongside breast cancer, is among the most common cancers affecting women3. In the US alone, approximately 20 million ultrasound exams are performed annually for thyroid and breast combined.4 With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant.”
Dr. Berger added, “Early deployment of See-Mode’s FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode’s automated detection and reporting.5 With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode’s technology should improve our ability to drive better access and more revenue through RadNet’s existing centers. Furthermore, there is already a reimbursement code that makes a portion of our approximately 250,000 annual thyroid ultrasounds eligible for additional reimbursement. We aim to expand these efficiencies to breast screening and other clinical areas in our more than two million annual ultrasound studies. These opportunities will also be sold and marketed by DeepHealth to third parties as we further commercialize the offerings.”
Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: “Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth’s combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound.”
Kees Wesdorp, President and CEO of RadNet’s Digital Health division, commented: “We are excited to integrate See-Mode’s technology in thyroid and breast ultrasound into DeepHealth’s comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team’s expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth.”
For more information, visit www.radnet.com and www.see-mode.com.
- See-Mode’s thyroid and breast solutions are cleared for distribution and marketing in Canada, Singapore, Australia, and New Zeeland, and its thyroid solution has additional FDA clearance in the United States.
- American Thyroid Association. (2017, February). Clinical Thyroidology for the Public, 10(2), 9. www.thyroid.org/patient-thyroid-information/ct-for-patients/february-2017/vol-10-issue-2-p-9/
- https://cancerstatisticscenter.cancer.org/
- Diagnostic Imaging Procedure Volumes Database 2024. Signify Research. Published October 4, 2024.
- Data on file. Initial deployment at 12 RadNet outpatient imaging centers.
March 13, 2026 
